Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

NCT04647526 is registered in ClinicalTrials.gov with POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.

NCT NCT04647526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 25, 2021
Completion date
March 31, 2028
Enrollment
455 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer